fetal and adult testis expressed 1Genealiases: CT43 · FATE
Q-omics provides the consensus-scored FATE1 profile across patient tissues and cancer cell-line models. FATE1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FATE1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FATE1 RNA expression shows 12,258 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where FATE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FATE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FATE1 survival associations across molecular data types. FATE1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FATE1 RNA expression–survival associations across cancer types. High FATE1 expression shows unfavorable associations in KIRP, ACC, UVM, GBM and LIHC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for FATE1 RNA expression.
This table summarizes FATE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FATE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FATE1 shows higher tumor expression in KIRC, LIHC, THCA, CHOL, LUAD and STAD. The KIRC box plot shows higher FATE1 RNA expression in tumor versus normal tissue (log2 FC = +2.311, t-test p < 0.001).
This table shows molecular features associated with FATE1 in patient tissues and cancer cell lines. In patient samples, FATE1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FATE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
